CFDA's Order On Chinese Pharmacopoeia Could Lead To Greater Testing Of Imported Medicines
This article was originally published in SRA
Executive Summary
Foreign medicinal products entering China could face greater testing at customs ports and encounter potential hurdles - especially with regard to products not included in the revised Chinese Pharmacopoeia (ChP) - following the China Food and Drug Administration's recent notice reinforcing the applicability of ChP to all imported drugs, say lawyers at Sidley Austin1,2.